Working… Menu

Effects of Oral Levosimendan on Respiratory Function in Patients With ALS: Open-Label Extension (REFALS-ES)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03948178
Recruitment Status : Completed
First Posted : May 13, 2019
Last Update Posted : January 26, 2021
Information provided by (Responsible Party):
Orion Corporation, Orion Pharma

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : November 18, 2020
Actual Study Completion Date : November 18, 2020